Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma (MM) incorporating iberdomide, isatuximab, and dexamethasone – the IBIS study amarc 20-01.

View Full Paper
Ask AI
Bookmark
Share

Authors

SMSridurga MithraprabhuJRJohn ReynoldsWJWojciech Janowski

Discussion

Loading...

Member takes

Overview

Interim analysis shows IB-IS-DEX improves progression-free survival in functional high-risk multiple myeloma patients, highlighting effective genomic analysis tools.

Key Points

  • To establish the efficacy and safety of an immune-therapeutic salvage strategy using iberdomide, isatuximab, and dexamethasone for patients with functional high-risk multiple myeloma.
  • Conducted the IBIS trial combining iberdomide, isatuximab, and dexamethasone treatment in functional high-risk multiple myeloma patients.
  • Utilized whole genome sequencing and genomic analysis of circulating tumour DNA to evaluate treatment effectiveness.
  • Evaluated overall response rate and safety at the end of 12 cycles of treatment.
  • Out of 29 evaluable patients, 20 achieved a best response of ≥PR, resulting in an overall response rate of 69.0%.
  • At 9 months, preliminary estimates indicated 51% progression-free survival and 82% overall survival.
  • The most common adverse events included neutropenia, insomnia, and infusion reactions.

Cite This Study

Mithraprabhu et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d190https://doi.org/10.1182/blood-2025-5841
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Isatuximab with bortezomib, cyclophosphamide, and dexamethasone followed by isatuximab and lenalidomide maintenance in newly diagnosed multiple myeloma patients with severe renal impairment: Final analysis of a phase 2 study by the greek myeloma study group2025
  2. 2Isatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI)2025
  3. 3Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)2025 · 1 citations
  4. 4Final results of a multi-center phase 2 trial of isatuximab-lenalidomide in patients with high risk smoldering multiple myeloma (HRSMM)2025 · 1 citations
  5. 5Double hit ultra-high risk myeloma treated with isatuximab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide (Isa-VRDc) induction and isa-VRD consolidation: Initial results of the UK myeloma research alliance (UKMRA) RADAR trial in newly diagnosed transplant eligible patients2025